European Association of Urology
Guidelines
Education & Events
Join our events Join our events
On-demand education Learn at your own pace
Scholarships Enrich your capabilities
Exchange Programmes Urology beyond Europe
Education Educational Platforms Talent Incubator Programme Accreditation
Science & Publications
Publications Our publications
Research & Science Passionate about research?
About
Who we are Our mission and history
Our Board and Offices How we work
Join the EAU Find out about membership
Vacancies Contact

Prof. James Catto (GB) shares results of THOR-2 cohort 1 study

In this podcast, UROONCO BCa chief editor Dr. Benjamin Pradere (FR) talks with Prof. James Catto (GB) about the THOR-2 cohort 1 study: Results of erdafitinib (ERDA) vs intravesical chemotherapy (chemo) in patients with high-risk non-muscle-invasive bladder cancer (NMIBC) with select fibroblast growth factor receptor alterations (FGFRALT) who received prior bacillus calmette-guérin (BCG) treatment.

Published Sun, 12 Nov 2023
PodcastBladder Cancer

Prof. Catto shares details on the rationale and design of the THOR-2 cohort 1 study, the results he presented at ESMO 2023, and some important take-home messages.

For more details on this study, you can read this abstract on the UROONCO Bladder Cancer educational platform.

Contact our organiser

Email:  podcast@uroweb.org

Share this event

About EAU
  • Who we are
  • How we work
  • Become a member
Services
  • MyEAU
  • Congress registrations
  • Abstract submission
Media
  • EAU News
  • EAU Newsletter
  • EAU Press Releases
Contact

  • EAU Central Office
    PO Box 30016
    NL-6803 AA ARNHEM
    The Netherlands

  • Contact us
About EAU
Who we areHow we workBecome a member
Services
MyEAUCongress registrationsAbstract submission
Media
EAU NewsEAU NewsletterEAU Press Releases
Contact

EAU Central Office
PO Box 30016
NL-6803 AA ARNHEM
The Netherlands

Contact us
European Association of Urology
Privacy PolicyDisclaimer